# Registry for the EVolution Of LUng Cancer Therapy Implementation and Outcomes Now

> **NCT02835599** · — · TERMINATED · sponsor: **AstraZeneca** · enrollment: 23 (actual)

## Conditions studied

- Non-Small-Cell Lung Cancer

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT02835599
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** TERMINATED
- **Start date:** 2016-11-01
- **Primary completion:** 2017-04-06
- **Final completion:** 2017-04-06
- **Target enrollment:** 23 (ACTUAL)
- **Why stopped:** The study sponsor requested the study be terminated as the existing study design did not meet their needs.
- **Last updated:** 2017-08-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02835599

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02835599, "Registry for the EVolution Of LUng Cancer Therapy Implementation and Outcomes Now". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT02835599. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*